Yonsei Med J.  2007 Apr;48(2):201-209. 10.3349/ymj.2007.48.2.201.

Influence of Combined Methionine Synthase (MTR 2756A > G) and Methylenetetrahydrofolate Reductase (MTHFR 677C > T) Polymorphisms to Plasma Homocysteine Levels in Korean Patients with Ischemic Stroke

• Kim OJ
• Hong SP
• Ahn JY
• Hong SH
• Hwang TS
• Kim SO
• Yoo W
• Oh D
• Kim NK

• KMID: 1779521
• DOI: http://doi.org/10.3349/ymj.2007.48.2.201

Abstract

PURPOSE
Methionine synthase (MTR) and 5,10-methylenetetrahydrofolate reductase (MTHFR) are the main regulatory enzymes for homocysteine metabolism. The present case- control study was conducted to determine whether there is an association between the MTR 2756A > G or MTHFR 677C > T polymorphism and plasma homocysteine concentration in Korean subjects with ischemic stroke. MATERIALS AND METHODS: DNA samples of 237 patients who had an ischemic stroke and 223 age and sex-matched controls were studied. MTR 2756A > G and MTHFR 677C > T genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). RESULTS: Frequencies of mutant alleles for MTR and MTHFR polymorphisms were not significantly different between the controls and cases. The patient group, however, had significantly higher homocysteine concentrations of the MTR 2756AA and MTHFR 677TT genotypes than the control group (p=0.04 for MTR, p=0.01 for MTHFR). The combined MTR 2756AA and MTHFR 677TT genotype (p= 0.04) and the homocysteine concentrations of the patient group were also higher than those of the controls. In addition, the genotype distribution was significant in the MTHFR 677TT genotype (p=0.008) and combined MTR 2756AA and MTHFR 677TT genotype (p=0.03), which divided the groups into the top 20% and bottom 20% based on their homocysteine levels. CONCLUSION: The results of the present study demonstrate that the MTR 2756A > G and MTHFR 677C > T polymorphisms interact with elevated total homocysteine (tHcy) levels, leading to an increased risk of ischemic stroke.

Keyword

Methylenetetrahydrofolate reductase (MTHFR); Methionine synthase (MTR); Ischemic stroke; Hyperhomocysteinemia; Polymorphism

Reference

1. Harmon DL, Shields DC, Woodside JV, McMaster D, Yarnell JW, Young IS, et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol. 1999. 17:298–309.

2. Lucock M, Daskalakis I, Briggs D, Yates Z, Levene M. Altered folate metabolism and disposition in mothers affected by a spina bifida pregnancy: influence of 677c → t methylenetetrahydrofolate reductase and 2756a → g methionine synthase genotypes. Mol Genet Metab. 2000. 70:27–44.

3. Castro R, Rivera I, Ravasco P, Jakobs C, Blom HJ, Camilo ME, et al. 5,10-Methylenetetrahydrofolate reductase 677C→T and 1298A→C mutations are genetic determinants of elevated homocysteine. QJM. 2003. 96:297–303.

4. Chango A, Boisson F, Barbe F, Quilliot D, Droesch S, Pfister M, et al. The effect of 677C→T and 1298A→C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects. Br J Nutr. 2000. 83:593–596.

5. Friedman G, Goldschmidt N, Friedlander Y, Ben-Yehuda A, Selhub J, Babaey S, et al. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. J Nutr. 1999. 129:1656–1661.

6. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995. 10:111–113.

7. Perini F, Galloni E, Bolgan I, Bader G, Ruffini R, Arzenton E, et al. Elevated plasma homocysteine in acute stroke was not associated with severity and outcome: stronger association with small artery disease. Neurol Sci. 2005. 26:310–318.

8. Howard VJ, Sides EG, Newman GC, Cohen SN, Howard G, Malinow MR, et al. Changes in plasma homocyst(e)ine in the acute phase after stroke. Stroke. 2002. 33:473–478.

9. Kim NK, Choi BO, Jung WS, Choi YJ, Choi KG. Hyperhomocysteinemia as an independent risk factor for silent brain infarction. Neurology. 2003. 61:1595–1599.

10. Choi BO, Kim NK, Kim SH, Kang MS, Lee S, Ahn JY, et al. Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small-artery occlusions. Thromb Res. 2003. 111:39–44.

11. Girelli D, Martinelli N, Pizzolo F, Friso S, Olivieri O, Stranieri C, et al. The interaction between MTHFR 677 C→T genotype and folate status is a determinant of coronary atherosclerosis risk. J Nutr. 2003. 133:1281–1285.

12. Lievers KJ, Boers GH, Verhoef P, den Heijer M, Kluijtmans LA, van der Put NM, et al. A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk. J Mol Med. 2001. 79:522–528.

13. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 1996. 94:2410–2416.

14. Spence JD, Malinow MR, Barnett PA, Marian AJ, Freeman D, Hegele RA. Plasma homocysteine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area. Stroke. 1999. 30:969–973.

15. Zintzaras E. Association of methylenetetrahydrofolate reductase (MTHFR) polymorphism with genetic susceptibility to gastric cancer: a meta-analysis. J Hum Genet. 2006. 51:618–624.

16. Hur M, Park JY, Cho HC, Lee KM, Shin HY, Choi HI. Methylenetetrahydrofolate reductase A1298C genotypes are associated with the risks of acute lymphoblastic leukaemia and chronic myelogenous leukaemia in the Korean population. Clin Lab Haematel. 2006. 28:154–159.

17. Song KS, Song JW, Choi JR, Kim HK, Shin JS, Kim JH. Homozygous V/V (677C to T) and D/D (2756 G to A) variants in the methylenetetrahydrofolate and methionine synthase genes in a case of hyperhomocysteinemia with stroke at young age. Exp Mol Med. 2001. 33:106–109.

18. Kim NK, Chong SY, Jang MJ, Hong SH, Kim HS, Cho EK, et al. Association of the methylenetetrahydrofolate reductase polymorphism in Korean patients with childhood acute lymphoblastic leukemia. Anticancer Res. 2006. 26:2879–2881.

19. Kim JK, Kim S, Han JH, Kim HJ, Chong SY, Hong SP, et al. Polymorphisms of 5,10-methylenetetrahydrofolate reductase and risk of stomach cancer in a Korean population. Anticancer Res. 2005. 25:2249–2252.

20. Kim NK, Han JH, Oh D, Hwang SG, Chae KY, Kim HJ, et al. Methylenetetrahydrofolate reductase gene polymorphisms in patients with Down syndrome. Korean J Genet. 2004. 26:431–436.

21. Kim NK, Choi YK, Kang MS, Choi DH, Cha SH, An MO, et al. Influence of combined methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase enhancer region (TSER) polymorphisms to plasma homocysteine levels in Korean patients with recurrent spontaneous abortion. Thromb Res. 2006. 117:653–658.

22. Cronin S, Furie KL, Kelly PJ. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: evidence from a cumulative meta-analysis. Stroke. 2005. 36:1581–1587.

23. Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet. 1996. 4:1867–1874.

24. Klerk M, Lievers KJ, Kluijtmans LA, Blom HJ, den Heijer M, Schouten EG, et al. The 2756A > G variant in the gene encoding methionine synthase: its relation with plasma homocysteine levels and risk of coronary heart disease in a Dutch case-control study. Thromb Res. 2003. 110:87–91.

25. Chen J, Stampfer MJ, Ma J, Selhub J, Malinow MR, Hennekens CH, et al. Influence of a methionine synthase (D919C) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis. 2001. 154:667–672.

26. Morita H, Kurihara H, Sugiyama T, Hamada C, Kurihara Y, Shindo T, et al. Polymorphism of the methionine synthase gene: association with homocysteine metabolism and late-onset vascular diseases in the Japanese population. Arterioscler Thromb Vasc Biol. 1999. 19:298–302.

27. Tsai MY, Welge BG, Hanson NQ, Bignell MK, Vessey J, Schwichtenberg K, et al. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases. Atherosclerosis. 1999. 143:163–170.

28. Ma J, Stampfer MJ, Christensen B, Giovannucci E, Hunter DJ, Chen J, et al. A polymorphism of the methionine synthase gene: Association with plasma folate, vitamin B12, homocyst(e)ine, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 1999. 8:825–829.

29. Zhu H, Wicker NJ, Shaw GM, Lammer EJ, Hendricks K, Suarez L, et al. Homocysteine remethylation enzyme polymorphisms and increased risks for neural tube defects. Mol Genet Metab. 2003. 78:216–221.

30. Yates Z, Lucock M. Interaction between common folate polymorphism and B-vitamin nutritional status modulates homocysteine and risk for a thrombotic event. Mol Genet Metab. 2003. 79:201–213.

31. De Marco P, Calevo MG, Moroni A, Arata L, Merello E, Finnell RH, et al. Study of MTHFR and MS polymorphisms as risk factors for NTD in the Italian population. J Hum Genet. 2002. 47:319–324.

32. Wang XL, Duarte N, Cai H, Adachi T, Sim AS, Cranney G, et al. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis. 1999. 146:133–140.

33. Zhang G, Dai C. Gene polymorphisms of homocysteine metabolism-related enzymes in Chinese patients with occlusive coronary artery or cerebral vascular diseases. Thromb Res. 2001. 104:187–195.

34. Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991. 19:5444.

35. te Poele-Pothoff MT, van den Berg M, Franken DG, Boers GH, Jakobs C, de-Kroon IF, et al. Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem. 1995. 32:218–220.

36. Le Marchand L, Donlon T, Hankin JH, Kolonel LN, Wilkens LR, Seifried A. B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). Cancer Causes Control. 2002. 13:239–248.

37. Matsuo K, Suzuki R, Hamajima N, Ogura M, Kagami Y, Taji H, et al. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood. 2001. 97:3205–3209.

38. Goode EL, Potter JD, Bigler J, Ulrich CM. Methionine synthase D919G polymorphism, folate metabolism, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2004. 13:157–162.